{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:42:36Z","timestamp":1790674956117,"version":"4.1.0"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Prostate cancer represents the most common non\u2013skin cancer type in men. Unmet needs include understanding prognosis to determine when intervention is needed and what type, prediction to guide the choice of a systemic therapy, and response indicators to determine whether a treatment is working. Over the past decade, the \u201cliquid biopsy,\u201d characterized by the analysis of tumor cells and tumor cell products such as cell-free nucleic acids (DNA, microRNA) or extracellular vesicles circulating in the blood of cancer patients, has received considerable attention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONTENT<\/jats:title>\n                  <jats:p>Among those biomarkers, circulating tumor cells (CTCs) have been most intensively analyzed in prostate cancer. Here we discuss recent studies on the enumeration and characterization of CTCs in peripheral blood and how this information can be used to develop biomarkers for each of these clinical contexts. We focus on clinical applications in men with metastatic castration-resistant prostate cancer, in whom CTCs are more often detected and at higher numbers, and clinical validation for different contexts of use is most mature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY<\/jats:title>\n                  <jats:p>The overall goal of CTC-based liquid biopsy testing is to better inform medical decision-making so that patient outcomes are improved.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2018.287102","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T16:35:15Z","timestamp":1546446915000},"page":"87-99","source":"Crossref","is-referenced-by-count":126,"title":["Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility"],"prefix":"10.1093","volume":"65","author":[{"given":"Klaus","family":"Pantel","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Hille","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I","family":"Scher","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell College of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,1]]},"reference":[{"key":"2020022605455458100_B1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","article-title":"Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries","volume":"70","author":"Wong","year":"2016","journal-title":"Eur Urol"},{"key":"2020022605455458100_B2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ctrv.2016.12.005","article-title":"Strategies to design clinical studies to identify predictive biomarkers in cancer research","volume":"53","author":"Perez-Gracia","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2020022605455458100_B3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0090-4295(99)00471-9","article-title":"Clinical states in prostate cancer: toward a dynamic model of disease progression","volume":"55","author":"Scher","year":"2000","journal-title":"Urology"},{"key":"2020022605455458100_B4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabieres","year":"2016","journal-title":"Cancer Discov"},{"key":"2020022605455458100_B5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ccell.2017.01.002","article-title":"Liquid biopsies, what we do not know (yet)","volume":"31","author":"Bardelli","year":"2017","journal-title":"Cancer Cell"},{"key":"2020022605455458100_B6","doi-asserted-by":"crossref","first-page":"127rv3","DOI":"10.1126\/scitranslmed.3003180","article-title":"Beyond PSA: the next generation of prostate cancer biomarkers","volume":"4","author":"Prensner","year":"2012","journal-title":"Sci Transl Med"},{"key":"2020022605455458100_B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1039\/C3LC50644D","article-title":"Technologies for detection of circulating tumor cells: facts and vision","volume":"14","author":"Alix-Panabieres","year":"2014","journal-title":"Lab Chip"},{"key":"2020022605455458100_B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201303698","article-title":"Biology, detection, and clinical implications of circulating tumor cells","volume":"7","author":"Joosse","year":"2015","journal-title":"EMBO Mol Med"},{"key":"2020022605455458100_B9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41551-018-0190-5","article-title":"Profiling circulating tumour cells and other biomarkers of invasive cancers","volume":"2","author":"Poudineh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"2020022605455458100_B10","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B11","first-page":"104","article-title":"A sample preparation and analysis system for identification of circulating tumor cells","volume":"25","author":"Kagan","year":"2002","journal-title":"J Clin Ligand Assay"},{"key":"2020022605455458100_B12","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","article-title":"Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer","volume":"13","author":"Shaffer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022605455458100_B14","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B15","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","article-title":"Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system","volume":"13","author":"Riethdorf","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2018.01.011","article-title":"Clinical applications of the CellSearch platform in cancer patients","volume":"125","author":"Riethdorf","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"2020022605455458100_B18","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-10-2650","article-title":"Circulating tumor cells as biomarkers in prostate cancer","volume":"17","author":"Danila","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/PPO.0b013e31823e69ac","article-title":"Circulating tumors cells as biomarkers progress toward biomarker qualification","volume":"17","author":"Danila","year":"2011","journal-title":"Cancer J"},{"key":"2020022605455458100_B20","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol"},{"key":"2020022605455458100_B23","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am J Pathol"},{"key":"2020022605455458100_B25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urolonc.2009.03.016","article-title":"Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease","volume":"27","author":"Mostaghel","year":"2009","journal-title":"Urol Oncol"},{"key":"2020022605455458100_B26","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B28","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"2020022605455458100_B30","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1158\/1078-0432.CCR-16-1224","article-title":"The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population","volume":"23","author":"Heller","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B31","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1055-9965.EPI-08-1173","article-title":"Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020022605455458100_B32","first-page":"6705","article-title":"Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer","volume":"34","author":"Okegawa","year":"2014","journal-title":"Anticancer Res"},{"key":"2020022605455458100_B33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.eururo.2016.07.051","article-title":"Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer","volume":"71","author":"Vogelzang","year":"2017","journal-title":"Eur Urol"},{"key":"2020022605455458100_B34","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B35","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.urology.2012.10.041","article-title":"Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer","volume":"81","author":"Amato","year":"2013","journal-title":"Urology"},{"key":"2020022605455458100_B36","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/j.1464-410X.2008.08327.x","article-title":"Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer","volume":"103","author":"Aragon-Ching","year":"2009","journal-title":"BJU Int"},{"key":"2020022605455458100_B37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","article-title":"A phase II clinical trial of sorafenib in androgen-independent prostate cancer","volume":"14","author":"Dahut","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2020022605455458100_B38","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-016-0268-6","article-title":"PSA and beyond: alternative prostate cancer biomarkers","volume":"39","author":"Saini","year":"2016","journal-title":"Cell Oncol (Dordr)"},{"key":"2020022605455458100_B39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1470-2045(15)00361-7","article-title":"Prostate cancer screening in men aged 50\u201369 years (STHLM3): a prospective population-based diagnostic study","volume":"16","author":"Gronberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020022605455458100_B40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.2017.75.2998","article-title":"Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials","volume":"36","author":"Heller","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur Urol"},{"key":"2020022605455458100_B43","unstructured":"Centers for Medicare & Medicaid Services. Local Coverage Determination (LCD): MolDX: Circulating Tumor Cell Marker Assays (L35710). https:\/\/www.cms.gov\/medicare-coverage-database\/details\/lcd-details.aspx?LCDId=37701&ver=3&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&KeyWord=oncotype&#x002B;prostate&KeyWordLookUp=Title&KeyWordSearchType=And&articleId=52974&bc=gAAAACAAAAAA& (Accessed November 2018)."},{"key":"2020022605455458100_B44","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.urology.2012.09.001","article-title":"Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer","volume":"80","author":"Folkersma","year":"2012","journal-title":"Urology"},{"key":"2020022605455458100_B46","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.juro.2008.06.021","article-title":"Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer","volume":"180","author":"Okegawa","year":"2008","journal-title":"J Urol"},{"key":"2020022605455458100_B47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clgc.2011.04.001","article-title":"Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer","volume":"9","author":"Goodman","year":"2011","journal-title":"Clin Genitourin Canc"},{"key":"2020022605455458100_B48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Visakorpi","year":"1995","journal-title":"Nat Genet"},{"key":"2020022605455458100_B49","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/bjc.2014.13","article-title":"Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer","volume":"110","author":"Merson","year":"2014","journal-title":"Br J Cancer"},{"key":"2020022605455458100_B50","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2020022605455458100_B51","doi-asserted-by":"crossref","first-page":"71447","DOI":"10.18632\/oncotarget.16169","article-title":"Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer","volume":"8","author":"Podolak","year":"2017","journal-title":"Oncotarget"},{"key":"2020022605455458100_B52","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Res"},{"key":"2020022605455458100_B53","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjc.2015.63","article-title":"Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents","volume":"112","author":"Crespo","year":"2015","journal-title":"Br J Cancer"},{"key":"2020022605455458100_B54","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"Ar-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2020022605455458100_B55","first-page":"122819","article-title":"Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer","volume":"pii","author":"Sharp","year":"2018","journal-title":"J Clin Invest"},{"key":"2020022605455458100_B56","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.2016.70.1961","article-title":"Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide","volume":"35","author":"Antonarakis","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.juro.2016.06.094","article-title":"Ar-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate","volume":"197","author":"Todenhofer","year":"2017","journal-title":"J Urol"},{"key":"2020022605455458100_B58","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1373\/clinchem.2017.281295","article-title":"In situ detection and quantification of AR-V7, AR-FL, PSA, and KRAS point mutations in circulating tumor cells","volume":"64","author":"El-Heliebi","year":"2018","journal-title":"Clin Chem"},{"key":"2020022605455458100_B59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23710","article-title":"Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression","volume":"79","author":"Tommasi","year":"2019","journal-title":"Prostate"},{"key":"2020022605455458100_B60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eururo.2017.01.011","article-title":"Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns","volume":"72","author":"De Laere","year":"2017","journal-title":"Eur Urol"},{"key":"2020022605455458100_B61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.eururo.2015.07.007","article-title":"Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells","volume":"68","author":"Onstenk","year":"2015","journal-title":"Eur Urol"},{"key":"2020022605455458100_B62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"71","author":"Scher","year":"2017","journal-title":"Eur Urol"},{"key":"2020022605455458100_B63","unstructured":"Centers for Medicare & Medicaid Services. Proposed Local Coverage Determination (LCD): MolDX: Oncotype DX AR-V7 Nucleus Detect for Men with Metastatic Castrate Resistant Prostate Cancer (mCRPC) (DL37915). https:\/\/www.cms.gov\/medicare-coverage-database\/details\/lcd-details.aspx?LCDId=37914&ver10.1200\/PO.17.000292&Cntrctr10.1200\/PO.17.00029All&UpdatePeriod10.1200\/PO.17.00029796&bc10.1200\/PO.17.00029AQAAEAAAAAAA& (Accessed November 2018)."},{"key":"2020022605455458100_B64","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1158\/0008-5472.CAN-17-1353","article-title":"Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer","volume":"77","author":"Scher","year":"2017","journal-title":"Cancer Res"},{"key":"2020022605455458100_B65","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","article-title":"Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer","volume":"4","author":"Scher","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020022605455458100_B66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5004","article-title":"The PROPHECY trial: multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)","volume":"36","author":"Armstrong","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B67","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"key":"2020022605455458100_B68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2016.07.021","article-title":"Expression of AR-V7 in circulating tumour cells does not preclude response to next generation androgen deprivation therapy in patients with castration resistant prostate cancer","volume":"71","author":"Bernemann","year":"2017","journal-title":"Eur Urol"},{"key":"2020022605455458100_B69","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdv282","article-title":"Serial blood-based analysis of AR-V7 in men with advanced prostate cancer","volume":"26","author":"Nakazawa","year":"2015","journal-title":"Ann Oncol"},{"key":"2020022605455458100_B70","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1373\/clinchem.2016.260299","article-title":"Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells","volume":"62","author":"Gorges","year":"2016","journal-title":"Clin Chem"},{"key":"2020022605455458100_B71","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science"},{"key":"2020022605455458100_B72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2159-8290.CD-16-1406","article-title":"An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer","volume":"8","author":"Miyamoto","year":"2018","journal-title":"Cancer Discov"},{"key":"2020022605455458100_B73","doi-asserted-by":"crossref","first-page":"34930","DOI":"10.18632\/oncotarget.9004","article-title":"Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer","volume":"7","author":"Gorges","year":"2016","journal-title":"Oncotarget"},{"key":"2020022605455458100_B74","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/j.clgc.2016.05.020","article-title":"PSMA theranostics using PET and subsequent radioguided surgery in recurrent prostate cancer","volume":"14","author":"Maurer","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"2020022605455458100_B75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.urolonc.2013.09.003","article-title":"The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research","volume":"32","author":"Ristau","year":"2014","journal-title":"Urol Oncol"},{"key":"2020022605455458100_B76","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol"},{"key":"2020022605455458100_B77","first-page":"5679","article-title":"Detection of circulating tumor cells in locally advanced high-risk prostate cancer during neoadjuvant chemotherapy and radical prostatectomy","volume":"35","author":"Thalgott","year":"2015","journal-title":"Anticancer Res"},{"key":"2020022605455458100_B78","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/j.juro.2008.01.102","article-title":"Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer","volume":"179","author":"Davis","year":"2008","journal-title":"J Urol"},{"key":"2020022605455458100_B79","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00432-014-1775-3","article-title":"Circulating tumor cell detection in high-risk non-metastatic prostate cancer","volume":"140","author":"Loh","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2020022605455458100_B80","first-page":"34235.e11","article-title":"Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer","author":"Meyer","year":"2016","journal-title":"Urol Oncol"},{"key":"2020022605455458100_B81","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.clgc.2015.04.003","article-title":"Circulating tumor cells in biochemical recurrence of prostate cancer","volume":"13","author":"Aragon-Ching","year":"2015","journal-title":"Clin Genitourin Canc"},{"key":"2020022605455458100_B82","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"2020022605455458100_B83","doi-asserted-by":"crossref","first-page":"39736","DOI":"10.1038\/srep39736","article-title":"Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients","volume":"6","author":"Kuske","year":"2016","journal-title":"Sci Rep"},{"key":"2020022605455458100_B84","doi-asserted-by":"crossref","first-page":"483.e9","DOI":"10.1016\/j.urolonc.2016.06.004","article-title":"Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer","volume":"34","author":"Todenhofer","year":"2016","journal-title":"Urol Oncol"},{"key":"2020022605455458100_B85","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.juro.2018.01.033","article-title":"Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms","volume":"199","author":"Chalfin","year":"2018","journal-title":"J Urol"},{"key":"2020022605455458100_B86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.69","article-title":"Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer","volume":"36","author":"Friedlander","year":"2018","journal-title":"J Clin Oncol"},{"key":"2020022605455458100_B87","doi-asserted-by":"crossref","first-page":"k3519","DOI":"10.1136\/bmj.k3519","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"2020022605455458100_B88","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/gm434","article-title":"Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing","volume":"5","author":"Heitzer","year":"2013","journal-title":"Genome Med"},{"key":"2020022605455458100_B89","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt.2892","article-title":"Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer","volume":"32","author":"Lohr","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2020022605455458100_B90","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/1541-7786.MCR-17-0539","article-title":"Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature","volume":"16","author":"Singhal","year":"2018","journal-title":"Mol Cancer Res"},{"key":"2020022605455458100_B91","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.molonc.2015.05.009","article-title":"Frequent expression of PD-L1 on circulating breast cancer cells","volume":"9","author":"Mazel","year":"2015","journal-title":"Mol Oncol"},{"key":"2020022605455458100_B92","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/annonc\/mdx206","article-title":"Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma","volume":"28","author":"Strati","year":"2017","journal-title":"Ann Oncol"},{"key":"2020022605455458100_B93","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41571-018-0074-3","article-title":"Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy","volume":"15","author":"Cabel","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2020022605455458100_B94","first-page":"1696","article-title":"Abiraterone in metastatic prostate cancer","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2020022605455458100_B95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/1\/87\/32638080\/clinchem0087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/65\/1\/87\/32638080\/clinchem0087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T05:55:33Z","timestamp":1582696533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/65\/1\/87\/5607896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,1]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2018.287102","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1,1]]},"published":{"date-parts":[[2019,1,1]]}}}